Altimmune Explores Obesity Drug as Potential Treatment for Alcohol Use Disorder
2025-03-13
Reuters
Altimmune announces plans to investigate its lead obesity drug, pemvidutide, as a potential treatment for alcohol use disorder and related health conditions, including alcohol-associated liver disease. This clinical trial aims to explore the therapeutic benefits of pemvidutide in addressing these conditions, offering new hope for individuals struggling with addiction and liver health issues. With a focus on innovative treatments, Altimmune is at the forefront of researching effective solutions for obesity, alcohol use disorder, and liver disease, utilizing cutting-edge medical research and clinical trials to drive progress.
